Journal
TRENDS IN MOLECULAR MEDICINE
Volume 19, Issue 4, Pages 250-261Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2013.02.002
Keywords
prostate cancer; RNAi delivery; non-viral vectors; gene therapy
Funding
- Irish Cancer Society [PCI11ODR]
- EMBARK Postgraduate Scholarship from the Irish Research Council for Science, Engineering, and Technology
Ask authors/readers for more resources
Prostate cancer is the most prevalent cancer in men of the United States and Europe, and although current treatments have efficacy in treating primary prostate cancer, they are associated with a decreased quality of life and are ineffective in treating the metastatic disease. The identification of oncogenes associated with the formation, proliferation, and metastasis of prostate cancer has presented promising targets for RNA interference (RNAi)-based gene therapy. However, the potential of RNAi as a successful therapeutic depends on effective delivery. In this review, we discuss the potential of targeting oncogenes implicated in prostate cancer with RNAi-based therapeutics using non-viral bioresponsive 'smart' delivery systems that work in harmony with the physiological and biochemical environments of prostate tumours.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available